| Oct 29 |
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
| Oct 26 |
LakeShore Biopharma Advances with Rabies Vaccine Trial
|
| Oct 25 |
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
|
| Oct 8 |
LakeShore Biopharma provides HY guidance
|
| Oct 8 |
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
|
| Sep 27 |
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
|
| Sep 4 |
LakeShore Biopharma appoints Wang as CEO
|
| Sep 4 |
LakeShore Biopharma Announces Leadership Transitions
|
| Aug 15 |
YS Biopharma reports FY results
|
| Aug 15 |
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
|
